New particles aim to shrink fibroids without surgery

NCT ID NCT06153667

Recruiting now Disease control Sponsor: Merit Medical Systems, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing Bearing nsPVA particles, used during a procedure called uterine artery embolization, to treat uterine fibroids in 100 women. The goal is to see if these particles safely block blood flow to fibroids, reducing symptoms like pain and heavy bleeding. Participants will be followed for 6 months to check for serious side effects and improvement in quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE FIBROID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyoma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE FIBROID

Contacts and locations

Locations

Alfred Health
RECRUITING

Sydney, Australia
Astra Vascular/Astra Vein Treatment Center
ACTIVE_NOT_RECRUITING

Brooklyn, New York, 11234, United States
Royal Gwent Hospital (Aneurin Bevan UHB)
RECRUITING

Newport, United Kingdom
The Wesley Hospital
RECRUITING

Brisbane, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.